By King & Wood Mallesons

Beijing Shenogen Pharma Group (“Shenogen”) raised RMB287.5 million (USD45.63 million) in its E1 round financing, which was closed on August 31, 2017, to support the development of SNG-162 (Icaritin). This round of investment was led by China Life AMP Asset Management Co., Ltd. 

Founded in 2008, Beijing Shenogen Pharma Group is a drug discovery and development company dedicated in development of therapeutics for cancer treatment. Shenogen possesses robust intellectual property rights on novel targets for anticancer therapies. SNG-162 (Icaritin), one of Shenogen’s most promising pipelines, is a first-in-class small molecule derived from traditional Chinese medicine specifically targeted at ER-alpha 36 for cancer treatment including breast cancer and liver cancer. The clinical trial phase III of SNG-162 (Icaritin) was launched at the Chinese PLA No.81 Hospital in Q4 2017 and is carried out at over 30 major liver cancer clinical centers in China.

King & Wood Mallesons has been Shenogen’s corporate counsel since 2008. King & Wood Mallesons acted as the legal counsel of Shenogen for E1 round financing. Heyi Rising Assets Management Co., Ltd., a strategic partner of KWM, acted as the financial advisor of Shenogen. The project was led by Lin Zhijun of KWM, and Kalley Chen of Heyi Group.